Knochensarkome – Diagnostik und Therapie

Knochensarkome sind seltene, bösartige Tumoren, die im Knochengewebe entstehen. Aufgrund ihrer Seltenheit und ihrer komplexen Natur erfordert die Behandlung von Knochensarkomen eine interdisziplinäre Herangehensweise, bei der verschiedene medizinische Fachrichtungen zusammenarbeiten. Der Artikel thematisiert neben der Epidemiologie und Diagnostik weiterführend auch die Therapie und Prognose der Erkrankung.

Schlüsselwörter

Osteosarkom - Knochensarkom - Chondrosarkom - Ewing-Sarkom

• Literatur

• 1 Strauss SJ, Frezz AM, Abecassis N. et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline fpr diagnosis, treatment and follow-up. Annals of Oncology 2021; 32: 1520-1536
• 2 National Comprehensive Cancer Network. NCCN Guidelines Version 1.2024 Bone Cancer. National Comprehensive Cancer Network. 2024
• 3 Hefti F. Kinderorthopädie in der Praxis. 3. Aufl. Heidelber: Springer; 2014
• 4 Mankin H, Mankin CJ, Simon MA. The hazards of biopsy, revisited. J Bone Joint Surg Am 1996; 78: 656-663
• 5 Hornicek F, Agaram N. Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surfical management. UpToDate Guidelines. Zugriff am:. 2023 https://medilib.ir/uptodate/show/7739
• 6 Anderton J, Moroz V, Marec-Bérard P. et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol. Trials 2020; 21: 96
• 7 Bajpai J, Chandrasekharan A, Talreja V. et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dose methotrexate-based, dose-dense combination chemotherapy regimen. Eur J of Cancer 2017; 85: 49-58
• 8 Whelan JS, Bielack SS, Marina N. et al. EURAMOS-1, an international randomized study for osteosarcoma: results from the pre-randomisation treatment. Ann Oncol 2015; 26: 407-414
• 9 Ferrari S, Bielack S, Smeland S. et al. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma aged over 40: Outcome in primary high-grade osteosarcoma. Tumori Journal 2018; 104: 30-36
• 10 Dürr HR, BakhshaiRechl H. et al. Resection Margins in Bone Tumors: What is adequate?. Der Unfallchirurg 2014; 117: 593-599
• 11 Winkelmann WW. Rotationplasty. Orthop Clin North Am 1996; 27: 503
• 12 Hanlon M, Krajbich JI. Rotationplasty in skeletally immature patients. Long term follow up results. Clin Orthop Relat Res 1999; 358: 75-82
• 13 Hillmann A, Hoffmann C, Gosheger G. et al. Malignant tumor of the distal part of the femur of the proximal part of the tibia: endoprosthestic replacement or rotationsplasty. Functional outcime and quality of life measurements. J Bone Joint Surg Am 1999; 81: 462
• 14 Krieg AH. Extracorporeal irradiation: Reimplantation of bone segments in the treatment of malignant bone tumours. Orthopäde 2017; 46: 681-687
• 15 Dong C, Beglinger I, Krieg AH. Personalized 3D-printed guide in malignant bone tumor resection and following reconstruction – 17 cases in pelvic and extremities. Surg Oncol 2022; 42: 101733
• 16 Ladenstein R, Pötschger U, Le Deley MC at al. Primary disseminated multifocal Ewing Sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010;
• 17 Kelley LM, Schlegel M, Hecker-Nolting S. et al. Pathological fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2.847 Consecutive Cooperative Osteosarcoma Study Group (COSS) patients. J Clin Oncol 2020; 38: 823-833
• 18 Ferrari S, Briccoli A, Mercuri M. et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long term survival. J Clin Oncol 2003; 21: 710-715
• 19 Cotterill SJ, Ahrens A, Paulussen M. et al. Prognostic factors in Ewings tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewings Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114
• 20 Dirksen U, Brennan B, Le Deley MC. et al. High Dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Inititative of National Groups, 99 Trial and EWING. J Clin Oncol 2008; 37: 3192-3202